Semaglutide vs Tirzepatide: Comparing GLP-1 Weight Loss Medications
By FormBlends Medical Team · Last updated: April 3, 2026
Tirzepatide has shown higher average weight loss in head-to-head clinical trials, largely due to its dual GIP/GLP-1 mechanism. Semaglutide has a longer track record with more safety data and broader prescriber experience. Both are effective, but the choice often comes down to individual response, insurance coverage, and whether the extra efficacy of tirzepatide justifies its newer status.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. Semaglutide targets only GLP-1 receptors; tirzepatide targets both GIP and GLP-1 receptors. Semaglutide is usually a better fit for people looking for a well-studied, proven glp-1 for significant weight loss with extensive safety data to back it up, while Tirzepatide is usually a better fit for people who want maximum weight loss potential or who did not respond well to glp-1-only medications. Cost also matters: Semaglutide is listed at $200-350/month compounded, $1,000-1,500/month brand, while Tirzepatide is listed at $250-400/month compounded, $1,000-1,500/month brand. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
FormBlends Comparison Context
Reviewed May 14, 2026Read Semaglutide Vs Tirzepatide comparison with the practical follow-up in mind. If the topic involves GLP-1 treatment, provider comparison, the next useful step is usually to verify evidence strength, access rules, pharmacy pathway, total cost, and the personal safety details that only a clinician can review.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
PubMed evidence trail
Research sources used to frame this page
For Semaglutide vs Tirzepatide: Comparing GLP-1 Weight Loss Medications, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Semaglutide vs Tirzepatide: Comparing GLP-1 Weight Loss Medications should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Head-to-Head Comparison
Semaglutide
GLP-1
Strengths
- Proven average weight loss of 15-17% body weight in clinical trials
- Available as both brand (Wegovy/Ozempic) and compounded
- Extensive long-term safety data from large trials
- Once-weekly injection with well-established dosing protocols
Weaknesses
- GI side effects like nausea are common, especially during titration
- Brand versions are expensive without insurance coverage
- Muscle loss can occur without resistance training
Best For
People looking for a well-studied, proven GLP-1 for significant weight loss with extensive safety data to back it up.
Typical Cost
$200-350/month compounded, $1,000-1,500/month brand
Tirzepatide
GLP-1
Strengths
- Dual GIP and GLP-1 receptor agonist hits two pathways
- Higher average weight loss in head-to-head trials (20-25% body weight)
- May improve insulin sensitivity more effectively than semaglutide
- Some patients report fewer GI side effects at equivalent efficacy
Weaknesses
- Less long-term safety data compared to semaglutide
- Brand versions (Mounjaro/Zepbound) are also very expensive
- Newer to market with less prescriber familiarity
Best For
People who want maximum weight loss potential or who did not respond well to GLP-1-only medications.
Typical Cost
$250-400/month compounded, $1,000-1,500/month brand
Key Differences
- 1Semaglutide targets only GLP-1 receptors; tirzepatide targets both GIP and GLP-1 receptors
- 2Tirzepatide showed 20-25% body weight loss in trials vs 15-17% for semaglutide
- 3Semaglutide has more years of post-market safety data
- 4Both are available in brand and compounded forms at very different price points
- 5Tirzepatide may have a slight edge for patients with insulin resistance
- 6GI side effects occur with both, though individual tolerance varies
Frequently Asked Questions
What is the difference between Semaglutide and Tirzepatide?
Semaglutide targets only GLP-1 receptors; tirzepatide targets both GIP and GLP-1 receptors. Tirzepatide showed 20-25% body weight loss in trials vs 15-17% for semaglutide.
Which is more effective, Semaglutide or Tirzepatide?
Tirzepatide has shown higher average weight loss in head-to-head clinical trials, largely due to its dual GIP/GLP-1 mechanism. Semaglutide has a longer track record with more safety data and broader prescriber experience. Both are effective, but the choice often comes down to individual response, insurance coverage, and whether the extra efficacy of tirzepatide justifies its newer status.
How much does Semaglutide cost compared to Tirzepatide?
Semaglutide typically costs $200-350/month compounded, $1,000-1,500/month brand, while Tirzepatide typically costs $250-400/month compounded, $1,000-1,500/month brand.
Who should choose Semaglutide over Tirzepatide?
Semaglutide is best for: People looking for a well-studied, proven GLP-1 for significant weight loss with extensive safety data to back it up.. Tirzepatide is best for: People who want maximum weight loss potential or who did not respond well to GLP-1-only medications..
Ready to get started?
Connect with a licensed provider who can help you decide between Semaglutide and Tirzepatide based on your goals, health history, and budget.